Tonix Pharmaceuticals is currently enrolling participants in a Phase 3 trial for military-related posttraumatic stress disorder.  For more information, please visit www.thehonorstudy.com or www.clinicaltrials.gov (NCT03062540).

Investor Relations

Investors

Latest News

Tonix Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Programs Update

Read Press Release

Upcoming Event

2018 Annual Meeting of the Shareholders

Offices of Lowenstein Sandler LLP - 1251 Avenue of the Americas, New York, New York 10020

Stock Information

Symbol

NASDAQ: TNXP

Price

Loading...

Change

Loading...

MKT Cap

Loading...

Volume

Loading...

52 week Low/High

Loading...

Day Low/High

Loading...

Company Overview

Tonix is a clinical-stage biopharmaceutical company focused on discovering and developing pharmaceutical products to treat serious neuropsychiatric conditions and biological products to improve biodefense through potential medical counter-measures. Tonix's lead product candidate, Tonmya, or TNX-102 SL, is in Phase 3 development as a bedtime treatment for PTSD. Tonix is also developing TNX-102 SL as a bedtime treatment for agitation in Alzheimer's disease. A Phase 2 IND (Investigational New Drug) application was submitted in March 2018 after completion of a successful pre-IND meeting with the FDA. TNX-601 (tianeptine oxalate) is in the pre-IND application stage, also for the treatment of PTSD but designed for daytime dosing. Tonix's lead biologic candidate, TNX-801, is a potential smallpox-preventing vaccine based on a live synthetic version of horsepox virus, currently in the pre-IND application stage.

IR Contact Information

Investor Relations
TONIX Pharmaceuticals
investor.relations@tonixpharma.com

Transfer Agent
vStock Transfer
77 Spruce Street
Suite 201
Cedarhurst, NY 11516
T: 212-828-8436
www.vstocktransfer.com